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Abstract
Breast cancer is the most common malignancy in women all over the world. Genetic background of women
contributes to her risk of having breast cancer. Certain inherited DNA mutations can dramatically increase the
risk of developing certain cancers and are responsible for many of the cancers that run in some families.
Regarding the widespread multigene panels, whole exome sequencing is capable of providing the evaluation
of genetic function mutations for development novel strategy in clinical trials. Targeting the mutant proteins
involved in breast cancer can be an effective therapeutic approach for developing novel drugs. This systematic review
discusses gene mutations linked to breast cancer, focusing on signaling pathways that are being targeted
with investigational therapeutic strategies, where clinical trials could be potentially initiated in the future are
being highlighted.
Keywords: Breast, New drug, Chromosome, Molecular patterns, Mutations
Introduction
Several risk factors was recognized to be associated with
breast cancer development including age, hormonal, re-
productive, menstrual history, alcohol, radiation, heredi-
tary factors, obesity, etc. [1]. Among these risk factors,
age is the biggest risk factor for developing breast cancer
followed by a positive family history. Based on data pre-
sented in literatures, previous studies discovered several
features of inherited mutations in the genes. It was esti-
mated that about 10–30% of breast cancer cases are re-
lated to hereditary factors, also 5–10% of breast cancers
were detected with strong hereditary factors, while be-
tween 4 and 5% of these cases was identified by muta-
tions in high-penetrant genes [2].
BRCA1 and BRCA2 have been known as regulators of
DNA repair, transcription, and cell cycle in reply to
DNA damage. BRCA1 and BRCA2 genes are the most
commonly mutated genes that are associated with high
breast cancer risk [3, 4]. It has been reported that 60%
of hereditary breast cancers can be related to germline
mutations in either of these genes [5]. The number of
genes are associated with multiple cancer syndromes for
example phosphatase and tensin homolog protein
(PTEN) (Cowden syndrome), TP53 (Li-Fraumeni),
STK11/LKB1 (Peutz-Jeghers), ataxia telangiectasia
(ATM) (Louis-Bar Syndrome), and NBS1 (Nijmegen
breakage syndrome), but other genes associated with
hereditary breast cancer are emerging. Cancer predispos-
ing genes can be classified as high-penetrant genes
including BRCA2, BRCA2, TP53, STK11, and CDH1
[6–9]. On the other hand, the majority of gens can be
categorized as moderate-penetrant genes in most of the
breast cancer cases including CHEK2, ATM, CDH1,
NBS1, BRIP1, PALB2, BARD1, RAD50, and RAD51,
which are frequently mutated in the general population
and contribute in developing of breast cancer [3, 10, 11].
The present study try to focus on the spectrum of mu-
tations, polymorphisms, and variants in each gene which
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: younesi.l@iums.ac.ir
1Shahid Akbar Abadi Clinical Research Development Unit (ShCRDU), Iran
University of Medical Sciences (IUMS), Tehran, Iran
Full list of author information is available at the end of the article
Lima et al. Journal of Hematology & Oncology           (2019) 12:38 
https://doi.org/10.1186/s13045-019-0725-6
are linked to breast cancer as well as how it contributes
to the disease.
Current aspects and personalized medicine
There are several cancer syndromes in which the alleles
are located in a predominant autosomal dominant fash-
ion and thus lead to a high risk of neoplasm. In addition,
non-genetic factors have been revealed to be implicated
in mutation or other genetic changes. Together with
genetic changes in tumors, a variety of inherited genetic
changes in the genes are involved in drug metabolism,
which are capable of affecting therapeutic responses
(e.g., increasing toxicity of the drug). Advances in “phar-
macogenomic” science lead to providing a specific treat-
ment based on individual genetic information [12]. In
this regard, personalized medicine open an opportunity
for applying the correct therapeutic strategy at the ap-
propriate, with the least toxic or non-toxicity, and this
treatment should be appropriate for a suitable patient at
the right time, where treatment will rely on genetic
changes in everyone’s cancer. As a matter of fact,
future-oriented attitudes in the medical arena should be
taken into consideration because we need to keep in
mind that genetic testing will be able to help decide on
better therapies where the patient does not respond to a
certain treatment, because this approach can avoid re-
ceiving medications that are not likely to be helpful.
Given the personalized medicine, information about
genetic changes in the tumor can help to elucidate the
right therapeutic decision. The completion of the human
genome project and the continuous advancement in
genetic research will facilitate the diagnosis and treat-
ment of many diseases. Genomic studies developed to
increase the medical awareness and ability to produce,
analyze, and interpret effective genetic data. However,
their effects on clinical performance occur at a much
slower rate [13, 14]. Scientists now realize that changes
that occur in a person’s cancer may not occur in other
people with the same type of cancer, while the same can-
cerous changes may be found in a variety of cancers.
We now learn more about genomic changes (change
in number of copies, deletion, mutations, single-nucleo-
tide polymorphism) and the correlation of these muta-
tions with many types of cancers. These communication
studies help determine who is at risk for cancer [15]. It
is hoped that the genomic cancer will expand with the
use of whole-genome sequencing (WGS), DNA sequen-
cing technology, and cancer cell analysis enables re-
searchers to clearly reveal new genetic changes
associated with cancers, which is likely to be very benefi-
cial for the development of personalized medicine. Pro-
viding an integrated analysis and systematic
characterization of key genomic mutations in different
kinds of breast cancer (BC) subtypes can lead to
advances in the use of favorable diagnostic, therapeutic,
and preventative strategies. Cancer can be considered to
be a genomic disease that each tumor has a set of spe-
cific genetic alteration. In-depth understanding of the
genetic alteration and molecular mechanisms that
underlie regulation of gene expression profiles in BC
cells leads to favorable effective therapeutic approach
that is dedicated to the genetic profile of each person.
High-penetrant gene
BRCA1 and BRCA2
BRCA1 gene has large coding sequences on chromo-
some 17q, consisting of 22 exons coding exons [16, 17].
BRCA2 gene consist of 26 coding exons on chromosome
13q [18]; a large number of mutations of both men-
tioned genes were characterized worldwide. To the best
of knowledge, many mutations have been described in
the BRCA1 gene (1800 mutations) and the BRCA2 gene
(2000 mutations) based on the data presented in BC In-
formation Core that is available at https://research.nhgri.
nih.gov/bic/resources.shtml [19]. As indicated, different
mutations are capable of conferring risks of ovarian can-
cer or BC including missense mutations, intronic
changes, deletions, large rearrangements, and small
in-frame insertions [19, 20].
BRCA1 and BRCA2 are postulated to play a crucial
role in maintaining DNA integrity and are tumor sup-
pressor genes. Inherited mutation in the BRCA1 and
BRCA2 genes is caused by hereditary BC.
Current evidence suggests that specific inherited mu-
tations of BRCA1 and BRCA2 are attributed to an en-
hanced risk of female BC and ovarian cancer (OV).
These two genes are regarded to be approximately re-
sponsible for 6–7% of BCs, and 10% OV these rates vary
between different populations [3] and have been linked
to higher risks of different types of cancer [4]. However,
not all breast and breast-ovarian cancer families carry a
mutation in BRCA1 or BRCA2. Breast and ovarian can-
cers related to BRCA1 and BRCA2 mutations tend to
occur more often in younger ages than their nonheredi-
tary counterparts.
To the best of our knowledge, the majority of muta-
tions of the BRCA1/BRCA2genes in breast and/or ovar-
ian cancer families are point mutations or small
insertions and deletions spread over the coding sequence
and splice site junctions. It is noteworthy that large rear-
rangements in BRCA1and BRCA2 accounted for less
than 1% of evaluated patients suffering from hereditary
breast and ovarian cancer [21]. All of these mutations
are capable of shortening BRCA1 protein, leading to fail-
ing to its physiologic function [9]. Furthermore, aggres-
sive triple-negative breast cancer (TNBC) has also been
associated with sporadic mutations in BRCA1 [22, 23].
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In addition, 853 unique mutations, polymorphisms, and
variants in the BRCA2 genes were also reported [9].
Male BC is an uncommonly occurred malignancy, ac-
counting for 1% of all male cancers and 0.65% of all breast
tumors [24, 25], which remarkably diagnosed at an older
age in comparison with female (mean age 67 years). It is
worth noting that 10% of males with BC has found to at-
tributed to a genetic predisposition with BRCA2 as the
most frequent genetic mutation [26, 27], accounting for
4–40% of hereditary BC in men [28]. Accumulating evi-
dence indicates that BRCA1/2m mutations can be consid-
ered as clinically appropriate and relevant for determining
subtypes of HER2-positive/HER2-negative BC [20, 29, 30].
Ample evidence has indicated that BRCA1/2m testing
can hold great promise for identifying subjects with breast
cancer who receive effective platinum-based chemother-
apy and PARP inhibitors-based therapy [20]; because sub-
jects as a homogeneous group with breast cancer
exhibited to be negative for predictive biomarkers includ-
ing estrogen-receptor-positive (or ER+), PGR progester-
one receptor, and HER2 gene amplification or HER2
protein overexpression, when underwent chemotherapy
because of either their lack of molecular marker for the
targeted therapy or lack of specific therapeutic approach
for triple-negative breast cancer (TNBC) subtypes [31]. It
is worth noting that loss-of-function mutations in
BRCA1/2 has been revealed for approximately 20% of un-
selected TNBC patients, holding a great promise for the
development of accurate therapeutic approach [32]. We
mentioned findings obtained with PARPis, in preclinical
phases of development for which there is a growing body
of evidence of strengthening effects of platinum in vivo
[33–35], where synergism between PARPis and platinum
compounds has been revealed in BRCA mutated breast
cancer [36, 37]. Efficacy of the veliparib alone and its com-
bination therapy with carboplatin has been currently sug-
gested in subjects with gBRCA1/2 mutations-associated
metastatic breast cancer [38]. A phase II trial (BROCADE,
NCT01506609) evaluated veliparib (ABT-888) in combin-
ation with paclitaxel and carboplatin vs placebo, where
findings revealed a 77.8% vs. 61.3% response rate [36]. In
addition, benefit of veliparib combinations has been po-
tentially indicated by a phase III randomized prospective
trial (NCT 02163694) for patients suffering from
BRCA-associated metastatic BC. Olaparib monotherapy
offer opportunities for the development of therapeutic tar-
gets in patients suffering from HER2-negative metastatic
breast cancer and germline BRCA1/2 mutations, where
exhibited to be beneficial over standard therapy [39]. In a
phase 3 trial, talazoparib was used in comparison with
other therapeutic strategies of physician including capecit-
abine, gemcitabine, eribulin, and vinorelbine for treatment
of advanced breast cancer and a germline BRCA muta-
tion, where talazoparib use was found to be linked to
prolonged PFS, and a remarkable delay in time was re-
vealed for deterioration in global health status/quality of
life [40].
PARPi and other therapy that are being assessed in
clinical trial studies in breast cancer associated with
BRCA1/2m, including rucaparib, veliparib, niraparib,
talazoparib, and olaparib, are summarized in Table 1
based on the date adopted from clinicaltrials.gov.
Accumulating evidence suggests that BRCA1/2 muta-
tions can be considered as predictor of the response to
PARPi in patients suffering from metastatic breast cancer.
It is worth noting that PARPi has been currently con-
firmed for breast cancer therapy, which were clinically
evaluated; on the other hand, olaparib has been also intro-
duced for BRCA1/2 mutations carriers with HER2-nega-
tive metastatic breast cancer.
An increasing body of evidence indicated that
platinum-based regimen can be used for BRCA1/2 mu-
tation carriers with TNBC, for whom cancer chemother-
apy with anthracycline cannot be performed. However, it
should be taken into account that standard chemother-
apy is likely to be applied as long as more information
on the effect of platinum chemotherapy be available for
subjects with positive hormone receptor breast cancer
carrying BRCA1/2mutations [20].
STK11/LKB1
The serine/threonine kinase gene (STK11/LKB1) is a sub-
stantial tumor suppressor gene, which acts as an energy
metabolic sensor and is involved in cell polarity regulation
and mediation of apoptosis. The STK11 gene plays a key
role in cell proliferation via many targets, where a require-
ment has been suggested for the tumor suppressor func-
tion of this kinase and/or STK11 catalytic activity [41–43].
One of the most important downstream targets of LKB1
is the energy sensor AMP-activated protein kinase
(AMPK). LKB1 is capable of phosphorylating and activat-
ing the AMPK [44, 45]. Phosphorylation of AMPK led to
activation of TSC1/TSC2, suppression of the mTOR activ-
ity, and dephosphorylation of mTOR effectors, S6K and
4E-BP1, which are capable of regulating initiation of pro-
tein translation [46]. As a matter of fact, LKB1 is consid-
ered as a regulator of many pathways implicated in cell
growth and metabolism. In addition, mTOR plays an im-
portant role in integrating various cell signals for regulat-
ing cell growth [47]. The mTORC1 signaling pathway has
been identified to be initially downregulated by kinase ac-
tivity of STK11 protein, and phosphorylation of the major
downstream targets (e.g., S6K1 and S6) can be also pre-
vented by STK11 protein. Current evidence suggests that
phosphorylation of S6K1 and S6 can contribute to the in-
hibition of tumorigenesis and cell proliferation [41, 48, 49].
MTOR overactivation has been also explained to be related
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to hamartomatous tumor growth, when STK11 inactivation
is occurred in mic [50].
Germline mutations in this gene cause Peutz-Jeghers
syndrome (PJS) that is subsequently associated with
breast cancer [9]. Current evidence suggests that pa-
tients with PJS show a 54% risk of developing BC in
comparison with the healthy individuals [51]. STK11/
LBK1 mutations have been detected to be related to
estrogen-receptor positivity, which may work as causa-
tive factor of breast cancer in susceptible people.
Somatic mutations of LKB1was detected in sporadic
pulmonary, breast, pancreatic, and biliary cancers and
melanomas. Recent studies have indicated that muta-
tions on threonine kinase gene (on 19p) play a crucial
role in developing the PJS. This syndrome has been
shown to be responsible for the high susceptibility to
many cancers, especially over age 60. Mutations of a sin-
gle allele in LBK1 may be responsible for an aggressive
BC which can lead to decreasing survival time [52].
Based on the data presented by Juan et al. (2014),
downregulation of LKB1 has been found to be linked to
markers involved in BC prognosis such as decrease of
Table 1 Therapeutic approaches for breast malignancies in clinical trials in subjects with BRCA1 and BRCA2 mutations. Tables and
data are adopted from clinicaltrials.gov. (https://clinicaltrials.gov/)
Conditions (Title) Interventions of clinical trial Study type Study
completion
Metastatic breast cancer • Drug: Placebo, veliparib, and carboplatin Interventional, phase 2 2019
• BRCA1 and BRCA2 mutation carrier with BC
• Hereditary BC/OC with BRCA1 and BRCA2
• Drug: Letrozole, and placebo Interventional, phase 3 2022
• Recombinant hCG
• BRCA1 and BRCA2 mutation in BC
• Drug: Ovitrelle, and recombinant Hcg Interventional phase 4 2021
• OC, BC, and prostate cancer • Drug: Olaparib Interventional, phase 2 2018
• BRCA1 and BRCA2 mutation carrier
• BC and metastatic BC, and OC
• Drug: Rucaparib (CO-338; AG-014699 or
PF-01367338)
• Expression evaluation
Interventional, phase 2 2015
• BC metastatic
• BRCA1 and BRCA2 mutation carrier
• Drug: Olaparib therapy, and chemotherapy
with doctor’s choice
Interventional, phase 3 2019
• BRCA1 and BRCA2 mutation carrier in BC • Biological: Therapeutic estradiol
• Drug: Deslorelin, therapeutic testosterone
• Deslorelin combined with low-dose add-
back estradiol and testosterone
Interventional, phase 2 2019
• BRCA1 and BRCA2 mutation carrier in BC • Supplement: S0812: cholecalciferol
supplementation
Interventional, not applicable 2017
• BC
• Metastatic BC
• BRCA1 and BRCA2 mutation
• Drug: ABT-888 and temozolomide Interventional, phase 2 2020
• Human EGF2 negative carcinoma of breast
• BRCA1 and BRCA2 mutation
• Drug: Niraparib as neoadjuvant therapy Interventional, phase 1 2020
• Breast neoplasms • Drug: Dexamethasone, trabectedin Interventional, phase 2 2011
• Breast malignancy
• BRCA1 and BRCA2 mutation carrier
• Drug: Talazoparib (BMN 673) Interventional, phase 2 2018
• Breast neoplasms
• BRCA1 and BRCA2 mutation carrier
• Drug: Talazoparib (BMN 673): a PARP
inhibitor
• Drug: Physician’s choice




• Drug: Talazoparib Tosylate Interventional, phase 2 2019
• BC: Stage IV
• OC
• BRCA1 and BRCA2 mutation
• Drug: Carboplatin, eribulin, and veliparib Interventional, phase 2 2020
• Basal-like breast carcinoma
• BRCA1 and BRCA2 mutation
• Drug: Veliparib
• Laboratory evaluation and biomarker
assessment
Interventional, phase 1 2017
• Atypical ductal breast hyperplasia
• BRCA1 and BRCA2 mutation carrier
• Metformin hydrochloride as drug
• Placebo
Interventional, phase 3
• Atypical ductal breast hyperplasia
• BRCA1 and BRCA2 mutation
• Dietary supplement: curcumin
• Biomarker evaluation
Interventional, not applicable 2019
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ER/PR, E-cadherin, and HMW-CK. Knockdown of en-
dogenous LKB1 has been shown to contribute to dysreg-
ulation of cell polarity and invasive phenotype of BC
cells [53].
It has been recently indicated that two novel missense
mutations of STK11 are involved in disruption of STK11
function and an impairment of serine/threonine-protein
kinase STK11 activity. Therapeutic strategies aimed at
targeting the downstream targets of the mTOR signaling
pathway common to S6K1 and S6 are considered as po-
tential therapeutic targets against STK11-related cancer.
In addition, in order to reveal new tumor vulnerabil-
ities following LKB1 loss, profiling of the intracellular
and extracellular tumor environments would need to de-
termine LKB1 features [54]. Preclinical investigations
(e.g., xenografts, cell lines, and GEMMs) have suggested
that highly effective therapies will be achieved by target-
ing LKB1 vulnerabilities and metabolic therapies [54].
Lkb1/Pten-deficient genetically engineered mouse model
(GEMM) has been shown to be correlated with en-
hanced level of PD-L1 expression and lung squamous
cell carcinoma [55].
Immunotherapies have a considerable therapeutic
impact on cancer patients with melanoma and
NSCLC. Anti-PD-1 and PD-L1 therapies have been
suggested as potential therapeutic against tumor re-
currence and/or metastasis in LKB1-mutant SCC to
target TPCs after debulking tumor with a targeted in-
hibitor or surgery [54–56].
It is worth noting that targeting LKB1 tumors with
specific chemotherapy or metabolic therapies are re-
quired in preclinical trials, which cancer cell line
encyclopedia (CCLE) may be clinically helpful to offer
clues [57]
Based on the previous findings [58–60], KRAS inhibi-
tor or epigenetic regulators combined with targeted
therapies or energy stress agents may hold great promise
for LKB1/KRASG12C or BRG1/LKB1 co-mutated cancer.
More efficacious therapeutic options can be achieved for
developing personalized medicine in patients with LKB1
mutations by defining vulnerabilities and their appropri-
ate targeting drugs as well as preforming novel thera-
peutic strategies in both animal and cell-culture-based
models such as organoid models and 2D and 3D culture
systems [54]. In addition, orthotopic patient-derived
xenograft (PDX) models and GEMMs can be used for
providing LKB1 vulnerabilities—targeting therapies in
imaging-based preclinical [61–64].
TP53
TP53 gene at17p13 is responsible for producing TP53
tumor suppressor protein that is responsible to various
stress signals and suppression of cellular transformation
via mediating cell-cycle arrest, the cellular response
against oncogenic stress, and cell repair and apoptosis.
TP53 is related to Li-Fraumeni syndrome that is linked
to onset of a many malignancies such as BC, brain tu-
mors, leukemia, and lymphoma, and sarcomas, as well
as melanoma, lung cancer [8, 65, 66]. These small
mutations are located in exons 5–8, spanning the
DNA-binding domain of the protein [67]. TP53 muta-
tions are considered to be associated with development
of 20–40% of BCs, and 90% of cases suffering from
metastatic BC in the brain showed TP53 mutation [68].
TP53 mutation has an independent prognostic value in
breast cancer, while its predictive value is debated [69,
70]. It has been indicated that a single-nucleotide germ-
line mutational alteration at exon 10 codon 337 of TP53
(CGC to CAC) is responsible for a change in arginine to
histidine (R337H) that is associated to early onset BC
[71–74]. Based on the current evidence, overexpression
of missense mutant p53 was identified in different kinds
of cancers and the tumor-promoting GOF activities have
been also demonstrated, indicating its potential for tar-
geted therapy in cancers [75].
Regarding the pharmacological strategies, many mu-
tant p53-targeting agents have been provided by differ-
ent approach over the past decade, where mutant
p53-targeting agents in combination with chemothera-
peutic drugs (e.g., p53–Mdm2 inhibitors) hold promise
for synergies. Based on the data presented in the litera-
tures, rational design using structural knowledge and
random screening chemical libraries has been resulted in
developing small molecule reactivators of mut p53 pro-
teins. Achieving an attractive pharmacological ap-
proaches need to address chemical characteristics of hit
compounds and antitumor efficacy; however, these ap-
proaches for mutant p53 are challenging because of het-
erogeneity of mutant p53 and requiring restoration of
correct folding in a mutant protein [75].
Y220C-targeting compounds such as PK083 and PK7088
have been designed [76]. PK7088 indicated potential as tar-
gets for triggering apoptosis and Y220C-dependent cell
cycle arrest of tumorous cells [77].
PK11007 has been revealed to contribute to the inhib-
ition of both the growth and migration and induction of
apoptosis in p53-mutated breast cancer cell lines, indicat-
ing a potential strategy for subgroup with triple-negative
breast cancer [78]. The investigations on reactivation of
mutant forms of p53 by using NSC319726 (p53 R175H),
PK7088, PK083, PK5174 (p53 Y220C), PRIMA-1, and PRI-
MA-1Met are likely to yield the most effective targeting of
mutant p53 in [75, 79].
PRIMA-1 and PRIMA-1Met has been described to be
able to restore conformation of wild-type mutant p53,
where they have been found to be more effective at inhi-
biting tumor growth and inducing apoptosis in tumor
cells in mice mode. PRIMA-1 has been found to be
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implicated in reactivating mutant p53 by covalent bind-
ing of MQ per se, therefore, can serve as an approach
for designing mutant p53-targeting anticancer drugs
[75]. In addition, it has been revealed that PRIMA-1 is
capable of inhibiting growth of mut p53 breast cancer
cells [80, 81]. APR-246 has been further investigated pre-
viously by preclinical models, which exhibited an inhibi-
tory effect on the cell proliferation in breast cancer.
Importantly, APR-246 in combination with eribulin
has been suggested to be considerably effective at in-
hibition of synergistic cell growth in six different
p53-mutated BC cell lines [82]. Response to APR-246
has been also revealed to be linked to mutant p53 BC
cells or high protein levels as a predictive biomarker
for this response [83].
APR-246 has been clinically evaluated (phase I) in
hematologic and prostatic neoplasms [82]; however, it is
undergoing clinical trials in subjects suffering from some
malignancies (Table 2), while is not currently evaluated
in patients with breast cancer.
COTI-2, a third-generation thiosemicarbazone deriva-
tive, has been provided by CHEMSAS®, a multi-staged
computational platform. COTI-2 has been revealed to
have an effective anti-proliferative activity function in
many human cancer cell lines including tumors for
which cetuximab and erlotinib have been applied for
providing treatments. In p53 mutant triple-negative
breast cancers, COTI-2 has been described to be
potentially applicable in providing therapeutic strategy
for patients with this subform [83, 84].
Anticancer activity of COTI-2 has been found in many
kinds of human tumor cell lines and MDA-MB-231 Xeno-
graft model for breast cancer. COTI-2 has been found to
be involved in caspase signaling cascade, resulting in
apoptosis in tumorous cells. It has been suggested that the
use of COTI-2 is safe and well-tolerated in vivo [84].
COTI-2 phase-I clinical is currently undergoing for gyne-
cologic malignancies and head and neck squamous cell
carcinoma that is available on https://clinicaltrials.gov/ct2/
show/NCT02433626?cond=COTI%E2%80%912&rank=1.
CDH1
The E-cadherin gene (CDH1, OMIM192090) on
chromosome 16q is responsible for encoding the
E-cadherin [85], which has been demonstrated to play a
key role in cellular adhesion, cell motility, differentiation,
growth, migration, and signaling [86] as well as to func-
tion as a tumor suppressor of BC [87]. Carriers of CDH1
gene mutation are at lifetime risk of BC on the order of
40% to 50% [88].
CDH1inactivation not only is directly associated with
germline or SM but is also linked to loss of heterozygosity
(LOH) and promotor hypermethylation. CDH location of
the chromosome 16 is mostly related to LOH and loss of
tumor suppressor function in human breast cancer [88].
E-cadherin downregulation is most commonly associated
Table 2 APR-246 used in clinical trial among subjects suffering from some malignancies; Tables and data are adopted from
clinicaltrials.gov. (https://clinicaltrials.gov/)
Status of trial Conditions (Title) Interventions of clinical trial Study type Study completion time
Not yet recruiting
New
• Treatment of TP53 mutant
myelodysplastic Syndromes
(MDS)
• Drug: APR-246 + azacitidine and
Azacitidine
Interventional, phase 3 2020
Recruiting • Esophageal carcinoma • Drug: APR-246 Interventional, phases 1 and 2 2023
Recruiting • Myelodysplastic syndrome
with gene mutation





• Drug: APR-246 and Azacitidine
• Combination therapy with APR-246
and Azacitidine
Interventional, phases 1 and 2 2021
Recruiting • myeloid neoplasms with
TP53 mutant
• Acute myeloid leukemia
• Chronic myelomonocytic
leukemia
• Drug: APR-246 and Azacitidine Interventional, phases 1 and 2 2021
Active • BRAF V600 mutant melanoma • Drug: APR-246 and Dabrafenib Interventional, phases 1 and 2 2018
Active • P53 activation in platinum
resistant serous advanced
OC
• Drug: APR-246 and pegylated
liposomal doxorubicin hydrochloride
(PLD)
Interventional, phase 2 2019
Completed • Prostate cancer or refractory
hematologic cancer
• Drug: APR-246 Interventional, phase 1 2010
Active • Platinum sensitive recurrent
advanced serous OC
(mutated p53)
• Drug: APR-246 and Carboplatin
and PLD
Interventional, phases 1 and 2 –
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with LOH or promoter hypermethylation in breast
cancers.
A growing body of evidence indicated that LOH at
the long arm of chromosome 16 is involved in carcin-
omas in breast. LOH is known as a major mutation
for the E-cadherin alleles in developing of lobular
breast cancers [89].
It has been shown that individuals with germline mu-
tation are at risk of lobular breast cancer and colorectal
cancer [90]. Moreover, women carriers are at lifetime
risk of 40–54% of lobular breast cancer [91, 92].
Among subjects with invasive lobular breast cancers,
e-cadherin was not expressed [93, 94], whereas smaller
rate allocated to the atypical expression. This subtype is
mostly related to LOH of the wild-type allele of CDH1.
The ductal subtype is recognized to show high hetero-
geneity, with lower frequency [87, 95].
Invasive lobular breast carcinoma was shown to be
typically E-cadherin-negative and inactivating mutations
has been frequently found along with LOH of the
wild-type allele of CDH1. Moreover, somatic CDH1 mu-
tations were reported in breast cancer, lobular carcinoma
in situ (LCIS). It is worth noting that most of somatic mu-
tations are due to premature stop codons as a conse-
quence of insertions; subjects with LCIS have shown LOH
for 16q22.1, and under-expression of E-cadherin, as well
as SMs in the CDH1 in LCIS [96]. Novel CDH1 germline
mutations have been recently revealed in patients suffer-
ing from LBC without family history for gastric cancer.
On the other hand, CDH1 germline mutations have been
revealed to be capable of affecting hereditary lobular
breast cancer as an independent-HDGC syndrome [97].
Nevertheless, longtime follow-up is needed for preventing
a secondary diffuse gastric cancer.
Increasing evidence suggests that a family history of
multiple ILC at younger ages and/or history of early-onset
bilateral ILC can be markedly attributed to CDH1 germ-
line mutations [98].
The rates of women with lobular type of BC are un-
clear, as histologic findings have not been specified. In
addition, based on the available data, no higher age limit
was reported for patients suffering from family ILC; on
the other hand, BRCA1/2 mutations were not also ex-
cluded from all patients.
Prescribing CDH1 germline analysis should be taken
in to consideration for subjects with pathological con-
firmation of early-onsets ILC, for both personal and fa-
miliar background [98].
Subjects with CDH1mutations are advised to check
annual mammograms and breast MRIs starting at age
35 years due to high lifetime risk of developing LBC
[99, 100]. CDH1germline mutations have been sug-
gested to be also exclusive with BRCA1/2 alterations. In
addition, the risk of ILC has been defined to be very close
to the risk of BC in subjects harboring BRCA1/BRCA2
mutation, where intensive surveillance and screening can
be performed by yearly mastography and MRI at age
30 years [98, 101].
Moderate-penetrant genes
ATM
The ataxia telangiectasia (ATM) gene (on positions 22
and 23 of chromosome 11) [102] plays a key functional
role in cells’ response to DNA damage. It encodes a PI3
K-related protein kinase that is involved in activating
cellular responses to DNA double-strand breaks via phos-
phorylation of key factors in the DNA damage-response
pathway [103].
Individuals harboring one copy of ATM associated
with gene deletion in each cell are at a high risk of BC
[7, 104]; subsequently, cells with missed one copy of this
gene are capable of providing half the normal amount of
ATM protein, that lead to prevention of proper repair of
DNA damage, resulting in occurrence of mutations in
other genes [7].
Germline mutation in the ATM gene has been
estimated to attribute to a prevalence of around 0.5%
[104, 105]. It was estimated that heterozygous carriers of
ATM mutations have a twofold higher breast cancer risk.
An increasing body of evidence indicated that this risk can
be elevated in women under the age of 50 years [69, 106].
Women harboring the ATM c.7271 T as a pathogenic mu-
tation may confer higher BC risks [107], although it can
be debatable because of limited evidence [108, 109]. There
is increasing evidence of radiosensitivity in ATM mutation
carriers regarding mice models and in vitro experiments.
ATM mutations are likely linked to an increased level of
sensitivity to platinum-based antineoplastic drugs [110, 111].
In addition, inhibition of DDR kinases, such as ATM
and ATR, has been revealed to increase the response
to ionizing radiation in some kinds of cancer including
ovarian and cervical carcinoma in vitro, while was not
capable of increasing the response to platinum drugs
[112]. Furthermore, BRCA1 is markedly involved in hom-
ologous recombination in primary mouse somatic cells,
but not the ATM [113]. It is not worthy that further clari-
fication will require systematic and in-depth understand-
ing of platinum sensitivity and ATM-aberrant cancers.
Contradictory results have been reported regarding
radiotherapy in carriers of a pathogenic ATM variant
where emerging data has indicated increased toxicity,
and other evidence indicates clinical benefits [114].
However, high risk has been reported for contralateral
breast cancer in subjects with ATM missense mutations
who underwent radiotherapy, indicating a lack of proper
treatment with radiotherapy [115]. Targeting ATR can
be taken in to consideration, where single-agent ATR in-
hibitors revealed to be potential therapeutic agent for
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mantle cell lymphoma with ATM-deficiency [116]. Ac-
cumulating evidence demonstrates that ATR-checkpoint
kinase 1 (Chk1) pathway can be considered as potential
therapeutic strategies for ATM-deficient cancers. VE821,
VE822, and AZD6738 are ATR inhibitors which are used
in preclinical studies [117, 118]. AZD6738 is an analogue
of AZ20 that exhibited single-agent anti-tumor activity
across cancer cell lines in ATM-deficient [119, 120].
AZD6738 is currently applied in subject suffering from
solid tumors as a single-agent and/or in combination
with palliative radiotherapy (NCT02223923). Single
agent activity of PARP inhibitors has been demonstrated
in ATM-deficient tumor cells [121, 122]. Based on avail-
able data, the loss of both ATM and p53 function re-
sulted in an increased level of PARP cytotoxicity [123].
However, to the best of our knowledge, PARP inhibitors
have not been clinically investigated in ATM-deficient
tumors. Inhibitors of other potential DDR targets includ-
ing PARP, CHK1/2, WEE1, and DNA-PKcs are consid-
ered as novel therapeutic approach for development of
ATM and ATR inhibitors with the potential to improve
cancer outcome [124].
Chk1 inhibitors are currently being evaluated in clinical
studies, which help to fulfill the potential of the
anti-metabolite therapies and cytotoxic chemotherapy and
anti-metabolite therapies [125]. In addition, Chk1 inhibi-
tors are in clinical development, for which chemosensitiz-
ing activity and monotherapy have been indicated in ATM
[110]. V158411 single agent or in combination with cyto-
toxic chemotherapy are considered as clinical therapeutic
strategy for triple-negative breast cancer [125]. MK-8776
(SCH-900776) as Chk1 inhibitor has been suggested to
contribute to an increased level of cell death induced by
chemotherapy [110, 126]. Furthermore, antileukemia ac-
tivity of SCH900776 has been revealed in a phase I trial.
In preclinical studies, PF-00477736 and AZD7762 have
been proposed as chemotherapy sensitizers in cancer cells
or xenografts [127]. Some clinical trials for ATM-deficient
breast cancer is documented (ClinicalTrials.gov Identifier:
NCT02264678; NCT03565991).
CHEK2
CHEK2 gene at position 12.1(22q12.1) [128] provides in-
structions for making checkpoint kinase 2 proteins as a
tumor suppressor. This protein is implicated in the
DNA damage signaling pathway [129].
CHEK2 plays a crucial role in regulation of p53 func-
tion and BRCA1, and it stops the cell from dividing and
a single DNA building block at nucleotide sequence
1100delC can led to abnormality.
A particular germline mutation, CHEK2c.1100delC,
has been found to be not only linked to enhanced risks
of BC [130] and male breast cancer [131], but have also
been related to response to therapy [132]. While it
seems to occur with a frequency of 0.5–2% in European
individuals [133]. A previous study indicated that
women with homozygous CHEK2c.1100delC mutations
are at risk breast cancer, sixfold higher than heterozy-
gotes [134]. CHEK2p.I157T variant is linked to lower
breast cancer risk (∼ 1.5) [135]. Moreover, mutations in-
cluding S428F and CHEK2del5567 were identified in
other populations [136]. It has been reported that
CHEK2.S428F increase risks of female BC by about two-
fold [130]. In primary breast cancer, CHEK2 or TP53
mutations have been revealed to be involved in a func-
tional pathway linked to resistance to epirubicin and
anthracycline-based chemotherapy [132, 137]. Further-
more, it has been suggested that CHEK2 H371Y muta-
tion carriers may represent favorable response to
neoadjuvant chemotherapy [138]. However, contradict-
ory findings have been achieved in response to endo-
crine therapy and/or adjuvant chemotherapy [139–141].
To the best of our knowledge, information on the effect-
iveness of systemic therapy for breast cancer patients
with CHEK2 mutations are limited [141]. Further devel-
opment will require comprehensive and in-depth under-
standing of the CHEK2 1100delC-associated breast
cancer to provide further personalized therapy.
PALB2
PALB2 was known as a BRCA2-interacting protein that
localizes BRCA2 during homologous recombination and
double-strand break repair, which is located at chromo-
some 16p12.2 [142]. The PALB2 and BRCA2 proteins
are capable of helping the regulation of the cell growth,
and division of cell, as well as are as tumor suppressors.
Homozygous mutations in PALB2 are linked to Fanco-
ni’s anemia, while heterozygous mutations in PALB2 are
related to developing of breast cancer risk in women
with a clear family history of breast cancer [70, 143].
PALB2 loss-of-function mutations have been detected
to attribute to a risk of 0.6 to 3.9% in families with a his-
tory of BC among people from many countries. Despite
PALB2 variants are rarely identified in 1–4% of BRCA
negative families, but increasing evidence suggests its in-
creased risk for breast cancer as compared to BRCA2
mutations [3, 144]. However, PALB2 has been recently
emerged to be a moderate-penetrant gene for breast
cancer susceptibility.
Gene mutation in PALB2 increases breast cancer risk
about twofold [145, 146]. PALB2 mutant genes were also
found in European families with a history of breast
cancer [146].
Antoniou et al. (2014) investigated PALB2 mutations by
BRCAx BC study. They indicated that heterozygous
PALB2 mutations carriers by age of 70 are developing BC
as high as 35%, where age- and family history-dependent
BC risk has been generally revealed in the population
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[147]. The higher rate of PALB2 mutations indicates the
high risk of breast cancer in the carriers. Therefore,
PALB2 mutations can be genetic markers for the clinical
diagnosis and prognosis of BC because of their higher
rates.
The ample evidence suggests that PALB2 is involved in
DNA damage repair via the FA/HR pathway, where it
plays a role as a switch panel for triggering the repair of
DSB via HR [148–150]. It has been indicated that regula-
tion of PALB2 phosphorylation, ubiquitylation, and homo-
dimerization are involved in mediating this control [150–
152]. Inhibiting these signalizations can be considered as
an approach for sensitizing cells to DNA damaging agents,
which provides an opportunity to develop a putative tar-
get, PALB2, for accessing cancer treatment [150].
It is worth noting that determination of the full
spectrum of PALB2 mutations is required in familial
breast cancer, where larger case-control studies can re-
veal the implication of PALB2 mutation. Further devel-
opment will need in-depth understanding of the
functional properties of the variant spectrum for deter-
mining the pattern of PALB2 and defective DNA repair
in genesis and cancer treatment [153].
ATMs and CHEK2 are in dire need of prospective in-
formation to provide strong evidence for developing risk
management and therapeutic strategies.
PALB2 mutations can lead to disease progression,
while its modulation is potentially related to progression
of breast cancer, showing its role in preventing tumori-
genesis [150]. A growing body of evidence suggests that
PALB2 functions as a tumor suppressor, which is being
explored as targets for development of therapies strat-
egies against cancer. The “synthetic lethality” offer a
promising opportunity to develop novel therapy in terms
of personalized medicine in cancer, such as PARP inhibi-
tors [154]; nonetheless, PALB2 advantages for develop-
ment of a specific therapeutic strategy such as PARP
inhibitors is still not clear [148, 150, 155].
BRCA1-interacting protein 1 (BRIP1; FANCJ/BACH1)
BRIP1 has been defined to interact with the BRCA1,
which can be colocalized with BRCA1 at sites of DNA
damage, and helps in repairing damaged DNA [156].
BRIP1 gene is located at 17q22.2 near the BRCA1 locus
[157]. BRIP1 interactions related to BRCA1 function
suggested that BRIP1 have attracted the attention as a
candidate tumor suppressor gene.
The frequent breast carcinomas (wild-type) of BRCA
genes were documented but exhibit allelic losses at the
17q21-q22 region which indicates that this chromosomal
region may be as a breast cancer predisposing gene. On
the other hand, BRIP1 has been described to be bialleli-
cally inactivated in patients with Fanconi anemia (FA).
Recently, biallelic defects in PALB2 have been revealed
to be involved in FA subtype N [143, 158].
Mutation in one copy of the gene disturbs function of
BRIP1 protein [159], which loss of function or missing
of this marker can lead to lack of interaction with the
BRCA1 protein, leading to failing the repair of the dam-
aged DNA [160].
Previous researches reported that the inherited muta-
tion in the BRIP1 gene is associated with the increased
risk of breast cancer [161, 162]. In addition, in a study
by Seal et al. (2006), truncating mutations were identi-
fied in breast cancer families, although there are reports
of higher risks in some families [163]. BRIP1 germline
mutations are also associated with an increased risk of
ovarian cancer [164]. However, the effect of germline
BRIP1 mutations in the risk of breast cancer is still con-
troversial [165].
Studies suggest that the germline BRIP1 mutations can
be considered as a moderate risk for ovarian cancer
[166–168], and prophylactic surgery is taken into consid-
eration for patients carrying BRIP1 mutation [165, 169].
While there is some evidence that truncating variants in
BRIP1, especially p.Arg798Ter, are not substantially
attributed to the development of breast cancer risk
[166]. There is no consensus on the role of truncating
variants in BRIP1 in developing breast cancer, where
no large systematic studies have been performed for
providing clear evidence. It is noteworthy that large
systematic studies would be needed to estimate the
reliable risk association with genetic variants.
PTEN
Phosphatase and tensin homolog protein (PTEN) is a
lipid phosphatase that is encoded by the PTEN gene.
This gene was identified as a tumor suppressor with
such functions, including regulation of cell cycle, apop-
tosis, and metastasis [170]. Alterations in the cell cycle
regulation and a defective apoptotic response occurs in
cell lines with mutations on PTEN.
Mutation or inactivation of PTEN gene had occurred up
to 30% of breast cancers that can led to hyper-activation
of the PI3K/Akt signaling pathway. Germline mutations in
PTEN are the cause of Cowden’s disease and Bannayan–
Zonana syndrome, which is described as a high risk of de-
veloping breast cancer. Affected individuals are at risk up
to 50% for breast cancer [134] and also 20–50% of affected
females [171].
It has been defined that cytoplasmic PTEN is capable of
playing a primary role in regulating PI3K/AKT pathway as
a negative regulator, while nuclear PTEN depicts
tumor-suppressive function in a phosphatase-independent
manner (e.g., apoptosis, cell cycle arrest, DNA repair, and
regulation of chromosomal stability [172–174].
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PTEN plays central role in promoting tumorigenesis,
where loss of PTEN has been indicated to contribute to
the resistance to cancer therapy. Preclinical findings in-
dicated that AKT/mTOR pathway may be a good target
for preventing growth of PTEN-deficient tumors. As a
matter of fact, agents targeting PI3K or downstream
may be a valuable source of therapeutic targets for pre-
venting PTEN-deficient cancers, while agents acting at
the level of signaling nodes upstream of PI3K Cannot be
effective [174].
Knockdown of PTEN has been found to engage ErbB3
receptor tyrosine kinase activity and insulin-like growth
factor-1 receptor signaling by their activation and also
lead to increased level of PI3K and AKT activities, resist-
ance to the anti-estrogens tamoxifen and fulvestrant,
and cell proliferation, as well as hormone-independent
growth [174, 175].
A progressing body of evidence proposes that PTEN
deficiency can be liked to a decrease in sensitivity of
RTK inhibitors, while more clarification is required
for confirming this claim. As previously indicated,
PTEN loss has been found to be related to unfavor-
able response in trastuzumab-treated breast cancer
patients [176, 177].
Contradictory findings have been reported for PTEN,
where its loss was found to be linked to better response
in lapatinib-treated breast cancer patients, followed by
trastuzumab [177]. On the other hand, in a phase III
trial (NCCTG N9831, adjuvant trastuzumab was found
to be beneficial for subjects with HER2-positive BC car-
rying PTEN mutation [178].
Much of the research into breast cancers can be fo-
cused on functions or mechanisms of trastuzumab
anti-tumor action in patients with PTEN deficiency,
where PTEN status has been indicated to be related
to response of trastuzumab, an anti-HER2 monoclonal
antibody, for developing therapeutic strategies against
breast cancer.
In this regard, it has been revealed that pertuzumab binding
to the extracellular domain of HER2 can be capable of
blocking ligand-induced HER2/HER3 dimerization [179, 180]
and can result in induction of antibody-dependent cellular
cytotoxicity (ADCC) [181].
Many researches have focused on effect of PI3K/
AKT/mTOR pathway inhibitors in patients suffering
from advanced HER2+ breast cancer. BEZ235 as
PI3K/mTOR inhibitor in combination with trastuzu-
mab revealed to be capable of exhibiting a favorable
safety profile in patients with HER2-positive meta-
static breast cancer and PI3K pathway alterations.
PTEN and PIK3CA status was not found to be linked
to responses of PI3K/mTOR inhibitor BEZ235 and
Buparlisib (PI3K inhibitor) in individuals with HER2+
advanced BC with metastasis [182, 183].
Epidermal growth-factor receptor (EGFR) antibody and
EGFR inhibitors (e.g., cetuximab or panitumumab) have
been used for developing a promising strategy for the
colorectal cancer therapy in EGFR-expressing tumors (i.e.,
NCT01283334, NCT00522665, NCT01719380, NCT01
252628, NCT01256385) [184–187].
P110β catalytic isoform of PI3K (class IA) has been
demonstrated to be involved in driving phos-
phatidylinositol signaling in PTEN-deficient cancer cells,
where further development will need clinical investiga-
tions and in-depth understanding of the molecular
mechanisms to develop therapeutic option such as
p110β-specific inhibitors (NCT01458067). TORC1 in-
hibition has been shown to be favorable efficacy for
PTEN hamartoma tumor syndrome [188].
Further development will need in-depth understanding
of the PTEN deficiency beyond the PI3K pathway, and
genome instability as well as the effect of PTEN defi-
ciency in modulating drug sensitivity and resistance.
Table 3 summarized clinical trial cancers as new thera-
peutic approaches for patients with PTEN deficiency.
MRE11-RAD50-NBS1 (MRN)
The highly conserved MRE11–RAD50–NBS1 (MRN) is
known as a complex that plays an important role in
DNA double-strand break regeneration (DSBs) via hom-
ologous recombination and on-homologous end-joining
(NHEJ) pathways as well as in telomere maintenance,
DNA replication, and cell cycle checkpoints [189]. Di-
mers of the proteins encoded by MRE11A, RAD50, and
NBN are implicated in forming this complex [190–195].
Deregulations of DNA damage signaling, checkpoints,
and repair pathways has been revealed to be linked to can-
cer progression and genotoxic therapies response such as
ionizing radiation and diverse chemotherapeutics.
Based on the data presented in the literature, the
ATM/MRN-coordinated DNA damage response net-
work can be usually activated in early stages of different
kinds of cancer, which there has been increasing
evidence that suggests the DNA breakage and
oncogene-induced replication stress are partial. There-
fore, DNA damage response network has been consid-
ered to be potentially a barrier against cancer [195].
Individuals harboring biallelic mutant MRN complex
gens (only one gene) are sensitive to ionizing radiation
deficit in DNA DSB repair, and genome instability [191].
Germline homozygous mutations of individuals in NBS1
have been defined as Nijmegen breakage syndrome
(NBS), for which an increased risk of cancer can be
regarded. Among three genes in the MRN complex, the
inherited NBN gene change has the strongest evidence
to act as an intermediate-risk breast cancer gene. It has
been indicated that heterozygous germline mutations of
MRN complex can be potentially capable of developing
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different types of cancers such as breast and ovarian can-
cers such as BC and ovarian cancer (OC) [192, 193, 196],
indicating that carrier of a deleterious mutation in
NBN may be capable of increasing the risk about
two- to threefold [192]; however, its role is controver-
sial. Moreover, an increasing body of evidence indi-
cated tow mutations in MRE11A gene can lead to
under-expression of all MRN proteins in non-BRCA1/
2 BC families [197]. MRN defects have been described
to be associated with chromosome instability. On the
other hand, an increasing body of evidence supports
that MRN are under evolutionary pressure to coord-
inate cellular network responses to DNA damage as-
sociated with mutation, cancer progression, and
apoptosis [198]. There is a hypothesis that RAD50
can act as intermediate-risk BC and/or pancreatic
cancer gene, but has no strong evidence in supporting
this hypothesis [193–195].
Downregulation of the MRN and its function defect
has been found to be capable of resulting in DNA dam-
age, higher propensity for cellular destabilization, and
cell transformation in tumor-development. However,
controversial data are presented in the literature using
different cell lineages, where a complex association has
been found between expression level of MRN and car-
cinogenesis. MRN overexpression and its components
have been suggested to be linked to worse outcome and
chemoradiation resistance through its vital role in DNA
DSB repair while others studies have published contra-
dictory findings [199–203]. MRN expression has been
suggested to be a key influential factor in cancer cells re-
sponse to chemotherapy, radiation therapy, and the level
Table 3 Clinical trials cancers for treatment of patients with PTEN-deficient. Tables and data are adopted from clinicaltrials.gov.
(https://clinicaltrials.gov/)
Status of trial Conditions Interventions of clinical trial Study type Study completion
time
Recruiting • PTEN mutation and PTEN hamartoma
Tumor Syndrome (PHTS)
• Drug: RAD001 and placebo Interventional, phases 1
and 2
2019
Recruiting • Advanced solid tumors with PTEN or
PIK3CB mutations
• Anatomic stage III BC AJCC v8 and
anatomic stage IIIA BC AJCC
• Drug: Docetaxel, PI3Kbeta and
AZD8186 inhibitor
• Biomarker evaluation
Interventional, phase 1 2021
Completed • Cowden’s disease
• PHTS
• Fludeoxyglucose F 18 as
radiotherapy
• Drug: Sirolimus
Interventional, phase 2 2012
Recruiting • Cancer and solid tumors with AKT1,
2, 3 genetic changes, activating PI3K
mutations, PTEN mutations
• Drug: ARQ 751 Interventional, phase 1 2019
Active, not recruiting • Advanced cancers with PI3KCA
mutation, Positive/PTEN under-
expression
• Drug: Pazopanib and Everolimus Interventional, phase 1 –
Not yet recruiting • Metastatic BC with AR+ and PTEN+ • Drug: Alpelisib (BYL719), and
Enzalutamide (androgen receptor
inhibitor)
Interventional, phase 1 2021






Terminated • c-MET inhibitor; PI3K inhibitor, PTEN
mutations, homozygous del. PTEN neg.
• Drug: INC280 and Buparlisib Interventional, phases 1
and 2
23, 2016
Recruiting • Metastatic melanoma and PTEN loss,
malignancy of skin
• Metastatic melanoma





Recruiting • Carcinoma, squamous cell of head
and neck with PI3KCA mutation
and/or PTEN under-expression
• Drug: Copanlisib and Cetuximab Interventional, phases 1
and 2
2020
Completed • Advanced solid tumors with PTEN
deficiency
• Drug: GSK2636771 Interventional, phase 2 2016
Recruiting • Advanced cancers with somatic
mutation in BRCA1/2
• Mutations/or deletions in PTEN /or
PTEN under-expression
• Drug: Talazoparib Tosylate Interventional, phase 2 2020
Recruiting • BC with PIK3CA/AKT1/PTEN-alteration
• TNBC
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of apoptosis [199]. Recently, homologous recombination
repair of double-strand DNA breaks has attracted re-
searcher focus as a target to develop an appropriate
therapeutic strategy, e.g., PARP inhibitors for BRCA1/
2-deficient cancers [204, 205].
A progressing body of evidence reveals that MRN
complex mutation-related HR deficiency may be capable
of sensitizing cancer cells to PARP inhibitors therapy,
and might thus be applicable for providing a predictive
biomarker of PARP inhibitor-based therapy [206–208].
Nonetheless, the important role of the MRN complex
and its components has not been fully understood in
clinical trial to determine molecular mechanisms that
underlie regulation of the MRN and its influence in can-
cer progression, prognosis, and chemosensitivity.
RAD51
RAD51 and the family of RAD51-related genes are im-
plicated in encoding proteins that play their role in
interaction with a set of proteins such as BRCA1,
BRCA2, and PALB2 and p53 for repairing the damaged
DNA in cellular damage-sensing and cell cycle check-
point pathways [209, 210]. RAD51 recruitment to break
sites and recombinational DNA repair depend on the
RAD51 paralogs [211]. Mutations in RAD51 can led to
loss of RAD51 focus formation in response to DNA
damage [212]. RAD51C is considered as an important
part of the DNA double-strand repair; its biallelic muta-
tions were observed in ~ 1.3% of BRCA1/2-negative BC
and/or OC families [213].
There are many studies showing the presence of mutant
RAD51C mutations in breast cancer and/or ovarian can-
cer families, indicating RAD51C as a cancer-predisposing
gene [214, 215]. It is also linked to both Fanconi
anemia-like disorders. Moreover, it is worth noting that
the other RAD51 paralogs, such as RAD51D and
RAD51L1, may be related to breast and/or ovarian cancer
risk [216], although it needs to be proven by clinical sig-
nificance of these findings that is unknown.
It has been identified that 1.3% of BC and OC families
had RAD 51C mutations, where emphasized on a rare
mutations of BC cases in families [216]. Additionally,
Wenping et al. (2012) suggested that RAD51C mutations
are rarely occurred among high-risk BC and BC/OC
families [217].
RAD51 is known as a central homologous recombin-
ation (HR) implicated in HR pathway via catalyzing the
strand transfer for repairing the damaged area. It is cap-
able of forming a helical filament on single-strand over-
hangs that can be exonucleolitycally created on DSBs
during presynaptic step [218, 219].
Dysregulation of RAD51 is capable of impairing HR
and inducing aberrant genome rearrangements, genetic
phenomena that can be seen in a variety of cancers
[209]. However, upregulation of RAD51 has been re-
ported in many types of tumor cells [219, 220]. It is be-
lieved that high expression level of RAD51 protein can
be potentially able to develop a mechanism for compen-
satory alternative DNA repair, and compensating the
functional BRCA1 loss involving in survival of cancer
cells and tumorigenesis, e.g., metastatic progression of
triple-negative breast cancer [221–223]. Targeting of
RAD51 is linked to enhanced kinase signaling, indicating
other mechanism linked to loss of synthetic lethality. It
is noteworthy that kinase signaling in triple-negative
breast cancer has been described by various rewiring
phenomena as compensatory mechanisms for resistance
to therapy [224–226]. Current evidence indicates that a
combined targeting of RAD51 p38 can be linked to in-
hibition of cell proliferation in vitro and in vivo. Further-
more, depletion of RAD51 has been found to be linked
to enhanced ERK1/2 and p38 signaling. Targeting of
RAD51, PARPi, and p38 may provide a therapeutic ap-
proach for TNBC, without a synthetic lethal resistance,
through inducing pressure on the pathways of DNA
repair [227].
The role RAD51 in breast carcinogenesis has been sug-
gested by previous studies. Some investigations indicated
concomitant under-expression of BRCA1 and upregulation
of RAD51 in sporadic invasive ductal breast cancer. Contra-
dictory findings reported under-expression of both BRCA1
and RAD51 in BC cell lines and BC cells [209, 220, 228].
Based on the data presented in the literature, RAD51 has
been revealed to be a key target of miR-155 both in vitro
and in triple-negative BC. MiR-155 is capable of regulating
DNA repair process and sensitivity to IR via repression of
RAD51 in BC. As a matter of fact, miR-155 targeting of
RAD51 can be mainly involved in induction of a delay in
repair after IR exposure [229]. B02 has been introduced to
be efficiently capable of inhibiting DNA strand exchange
feature of RAD51, DSB repair, and DSB-dependent HR
[230]. An increased MDA-MB-231 cell killing has been re-
ported using B02 especially better efficacy has been
achieved in combination with cisplatin. B02 was also cap-
able of sensitizing MDA-MB-231 breast cancer cells to cis-
platin in mouse xenografts. Additionally, B02 resulted in
disruption of RAD51 foci formation in MDA-MB-231 cells;
therefore, it has been previously concluded that B02 can be
considered as an effective agent via targeting RAD51 in
vivo, indicating its potential to offer a promising combin-
ation strategy for the treatment of cancer [219]. Further de-
velopment would be needed to appropriately clarify the
molecular mechanisms of the RAD51 and its influence in
BC in order to develop new anti-cancer therapy.
BRCA1-associated RING domain 1 (BARD1; MIM #601593)
The human BARD1 gene spread out over long arm of
chromosome 2 (2q34-2q35) with an 85-kb region. The
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sequence and structure of BARD1 has been defined to
share similarities with BRCA1, forming a functional het-
erodimer with BRCA1 via RING fingers of both BRCA1
and BARD1. Both BARD1 and BRCA1 proteins possess
a RING finger domain at the N-terminus and two
C-terminal BRCT domains; RING domains demon-
strated E3 ubiquitin ligase activity, which play a vital role
in targeting proteins implicated in many biological
process such as cell-cycle regulation, DNA repair, and
modulation of chromatin structure [231]. Ubiquitin li-
gases demonstrated a major role for the initiation of
polyubiquitination, which are key proteins involved in
degradation by the proteasome. Mutations of BRCA1
RING domain lead to breast cancer by disrupting the E3
ubiquitin ligase activity of BRCA1-BARD1 [232]. The
BARD1/BRCA1 heterodimer has been found to be im-
plicated in homologous recombination DNA repair and
maintaining genomic stability, whereas defective func-
tion and/or dysregulation of either protein can be associ-
ated with genomic instability [233, 234]. Therefore, it
has been revealed that BARD1 plays crucial role in
maintaining genome integrity and cell viability [235].
BARD1 protein interacts with BRCA1 in DNA
double-strand break repair and initiation of programed
cell death [233, 236]. Based on the data presented in the
literatures, occurrence of missense mutations in the
BRCA1 RING-finger domain are capable of preventing
the formation of heterodimers, demonstrating very
slightly deleterious mutations [233, 235, 237].
It has been shown that missense mutations in the
BRCA1 RING-finger domain are capable of preventing
the formation of heterodimers, demonstrating very
slightly deleterious mutations [238]. Mutant BRCA1 and
BRCA2 gens are linked to emerging various hereditary
BC, accounting for 1% of all BC patients with a lifetime
risk of 50–85% [239, 240]. Increasing evidence suggests
that BARD1 mutations is very likely to occur in patients
with non-BRCA1/2 inherited breast cancer [241].
Some breast cancer-related BRCA1 missense muta-
tions disturb the function of the BRCA1/BARD1 com-
plex. In a previous study, missense BARD1 variant,
Cys557Ser (rs28997576), has been revealed to be highly
upregulated in breast cancer families [242, 243]. Mis-
sense mutations in BRCA1 (e.g., p.Cys61Gly) has been
shown to be capable of distracting the BARD1/BRCA1
interaction, thus leading to breast cancer [244].
Previous studies indicated that mutations in the RING
finger domain of BRCA1 are capable of making disturb-
ance to BRCA1/BARD1 interaction in BC [245] and the
presence of BARD1 missense mutations in subjects suf-
fering from BC revealed that BARD1 gene tendency to
participate in BRCA1 mediated tumor suppression [246].
Another study has reported a protein truncating muta-
tion (p.Glu652fs) in BARD1 gene among family with
great risk and also a homozygously deleted BARD1gene
in a BC family [247, 248]. Previous studies identified
BARD1 mutations in high-risk families [249].
Based on the data presented by large whole exome se-
quencing, BARD1 have merged among the genes with
somatic alteration at low level [250].
BRCA1 has a tumor suppressor role, which is
likely to be under control via the BARD1-BRCA1
heterodimer [231], and ubiquitination-dependent
pathways are involved in BRCA1 degradation [251].
As a matter of fact, BRCA1 protein plays its func-
tional role via ubiquitin ligase activity [12], thus is
capable of affecting DNA repair, and cell control
mechanisms, as well as mitosis, via targeting pro-
teins for degradation [232, 252, 253].
A set of data demonstrated that somatic mutations
and/or predisposition gene silencing variants can be as-
sociated with dysregulation of full-length BARD1 (FL
BARD1), which can be taken into attention as an early
hit of BARD1 tumor suppressor function. Furthermore,
cancer-related BARD1 isoforms have been shown to be
capable of antagonizing the functions of FL BARD1
tumor suppressor, resulting in genetic instability, DNA
repair-deficiency, and loss of cell cycle regulation and in-
creased cell proliferation [233].
Cancer-related isoforms of BARD1, except for
FLBARD1, can result in proliferation arrest in vitro
[232, 254, 255]. Current evidence suggests that pro-
tein interaction, pro-proliferative pattern, and
localization of BARD1 isoforms are found to be
highly different as compared to FL BARD1, indicating
that isoforms obtained tumor-promoting functions,
while losing tumor suppressor functions of FL BARD1
[232, 254]. Furthermore, FL BARD1 has been shown
to play a functional role in turnover of the mitotic
aurora kinases. Aurora kinases have been described to
be upregulated in various cancers leading to genetic
instability, thus its expression level can potentially be
considered as biomarkers for predicting response to
aurora inhibitors [235, 256, 257].
BRCA1 mutations have been reported to be associ-
ated with resistance to both PARPi and platinum as
therapeutic approach. BARD1β has been introduced
to evaluate the suitability of colon cancers for hom-
ologous recombination targeting using PARPi [233,
258–260]. Further investigations are necessary to ex-
plore the role BARD1 function in cancer in the future
as well as to determine the efficacy of PARPi in
BARD1 mutated gene with its defective function.
PARPi is explained to be involved in inducing mul-
tiple double-strand breaks therefore it can be highly
linked to repairmen of cell death, when double-strand
breaks in identified BRCAs (1 and 1) mutations are
repaired at low level in cancer [235, 261].
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EGFR, ERBB2, and activating ERBB2 (HER2) mutations
There are four members including EGFR, ERBB2
(HER2), ERBB3, and ERBB4 in the family of epidermal
growth-factor receptors (EGFRs). These receptors medi-
ate normal cell proliferation and cell survival via two
major signaling pathways: Ras-Raf-MAPK and PI3K/
Akt/mTOR. Considering breast cancer, high levels of the
EGFR and c-erbB2 correlate with poor prognosis be-
cause of a high incidence of metastases and intrinsic re-
sistance [262, 263].
The EGFR is robustly expressed in TNBC, and indi-
cated to be strongly related to poor prognosis. Moreover,
overexpression of the EGFR has been found in 20–25%
of BCs and was correlated with poor prognosis and
worst survival rates of BC subjects. It is worth noting
that the expression of transforming growth factor, and
TGF-α, and another EGF family member, named
amphiregulin, is the most commonly increased in BCs
[264]. High copies of ErbB2 led to overexpression of the
ErbB2 receptor protein. As result, high amount of ErbB2
receptor protein induces continuous signals for rapid
growth of cells and cell division which result in develop-
ing cancerous tumors. The non-receptor tyrosine kinase
Src, PI3K, and MAPK pathways mediates ErbB2 increased
proliferation, survival, motility, and invasion. ErbB2 plays
an important role in human malignancies [265]. The
erbB2 expression was detected to be increased in 20–30%
of human BCs ErbB2 (HER2) positive BC strongly related
to poor prognosis that result in emerging metastases na-
ture of cancer and intrinsic resistance to endocrine and
routine chemotherapy [266, 267].
The HER pathway has been defined to be related to
the pathogenesis of breast cancer, which are particu-
larly overexpressed in subjects with HER2 mutations
[268]. It has been previously estimated that wild-type
HER2 overexpression is linked to 20–30% of breast
cancers; however, another study indicated that HER2
mutation is contributed to 6% prevalence for breast
cancer subjects [269].
Many investigations have further described the occur-
rence of HER2 mutations in many kinds of solid tumors
(e.g., breast, non-small cell lung, colorectal, and bladder
cancers) by development of the Cancer Genome Atlas
projects [270–272], where their highly recurrent nature
and their presence in the kinase domain and/or extracel-
lular domain mutations at residues 309–310 have been
revealed [269, 273, 274]. In addition, it has been previ-
ously demonstrated how both oncogenic transformation
of breast epithelial cells and tumor growth enhancement
can be developed by HER2 mutations [269, 273], thus
leading to tumorigenesis. A host of approaches are being
evaluated HER2 mutation positive cases, where resistant
to the reversible HER2 inhibitor lapatinib has been re-
vealed; on the other hand, neratinib was reported to be
beneficial for treating the HER2 mutation positive subjects
[269, 275–278]. A study demonstrated that seven HER2
mutations activated the protein including V842I, R896C,
G309A, D769H, D769Y, V777 L, and P780ins, leading to
providing benefit from existing HER2-targeted drugs (ner-
atinib) for breast cancer patients with refractory HER2
positive [269].
Neratinib and/or neratinib-based combinations have
been considered for providing therapeutic strategies in
terms of HER2-mutated BC. As indicated in Table 4, dif-
ferent clinical phases of neratinib monotherapy and
neratinib-based combination have been developed for
treating the HER2 mutation positive patients by nerati-
nib (HKI-272) for which there is an increasing evidence
of encouraging therapeutic efficacy.
DIRAS3/ARHI (DIRAS family, GTP-binding RAS-like 3)
The DIRAS3 gene is defined as a member of Ras genes.
It has been mapped to the 1p31.3 [276]. ARHI is capable
of encoding a small GTP-binding protein of Ras family
that plays its role as a tumor suppressor gene in OV and
BCs [276, 279]. Two copy of DIRAS3 genes are inherited
from parents, and its expression from the paternal allele
has been described in all normal cells, namely genomic
imprinting. Based on the current evidence, ARHI
re-expression in breast and ovarian cancer cells has been
defined to be capable of activating JNK pathway, leading
to apoptosis and inhibition of tumor progression and
metastasis [280–282]. Ample evidence supports that de-
regulation of DIRAS3 function can be caused by a “sin-
gle hit” over period of carcinogenesis [276]. This
increases the susceptibility for developing of BC. To the
best of our knowledge, mutations of ARHI have not
been revealed for the coding and promoter areas [283].
DIRAS3 protein as an imprinted tumor suppressor
shows normal expression level in breast epithelial cells,
whereas is under-expressed in more than 70% of BCs.
Its downregulation is associated with developing of
tumor in BC [279].
STAT3 play a key role in regulating the methylation
status of many kinds of tumor suppressor genes, leading
to their downregulation such as ARHI. It has been indi-
cated that ARHI is capable of blocking nuclear transport
of STAT3 via interacting with STAT3 [280, 284]. On the
other hand, it has been revealed that ARHI is capable of
competing Ran proteins, and is involved in forming a
complex with importinβand, thus leading to prevention
of the nuclear transport of STAT3. A progressing body
of evidence reveals that downregulation of ARHI plays a
key role in regulating of machinery for nuclear transport
of STAT3, leading to upregulation of oncogenes in
tumor. In this regard, further in-depth understanding of
interacting mechanism of ARHI with STAT3 and impor-
tinβcan are needed to provide new molecules that can
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be capable of mimicking the interactions of ARHI pro-
tein with these proteins [280].
Previously, ARHI re-expression has been reported to
be implicated in inducing autophagic cell death in breast
cancer cells, and is able to increase the growth inhibitory
effect of paclitaxel through promotion via some bio-
logical process, e.g., apoptosis, autophagy, and G2/M cell
cycle arrest [283].
Androgen receptor
The human androgen receptor (AR) is a member of the
nuclear receptor superfamily, which is involved in hor-
mone action. The AR gene on chromosome Xq11-12 is
responsible for encoding a 110 kDa cytoplasmic protein.
The AR gene is located on chromosome Xq11-12 and
encodes a 110 kDa cytoplasmic polypeptide. AR can also
be activated through a non-transcriptional/non-genomic
mechanism that does not need. AR receptor is widely
expressed in 70–90% of all breast cancers and has been
suggested to be effective as therapeutic target in
ER-negative breast cancers, because it is widely
expressed in the most of ER-positive breast cancers (67–
88% of cases) with apocrine differentiation, which is re-
lated to a reduction in mortality [285–288].
Concerning the matters about ER-negative metastatic
breast cancer, AR expression was identified in 12–50%
of cases [289, 290], which is linked to lower rate of
survival [291].
There is an apolymorphic CAG trinucleotide repeat in
the AR gene. Based on the evidence, the CAG repeats
are usually occurred about 8 to 35 times in normal indi-
viduals [292]. It has been reported that breast cancer risk
may be influenced by indirect effect of androgens via
their conversion to estradiol, or by binding with AR to
promote or by stopping breast cell growth, or even by
binding to ESR1 and inducing proliferation in breast
cells [293]. Several specific mutant ARs have been detected
among BC patients [294, 295] in female breast cancers. Sev-
eral studies have revealed the CAG polymorphism, with
CAG repeats in the gene, which increased risk of develop-
ing BC in female gender. However, the correlation between
this polymorphism and BC has yielded conflicting results
[296]. Some studies suggest relationship of short or long
CAG repeats with BC [297–300]. On the other hand, dis-
crepant results have also reported no association [301, 302].
Nevertheless, the involvement of endogenous androgens in
developing BC is unclear.
There is not a clear association between AR signaling
and breast cancer risk. It has been emerged that AR sig-
naling is involved in breast cancer, but dichotomous as-
sociation of AR with ER status and molecular subtype.
Conflicting results are available in the literature, when
current evidence suggests different prognostic role of
AR among molecular subtypes, e.g., ER-negative BC and
ER-positive breast cancer [303, 304]. For instance, AR
has been recognized that AR in ER-negative breast can-
cer is able to bind a nucleus ligand, inducing cell prolif-
eration while, however, its activity remains equivocal in
ER-negative breast cancer. A phase II trial indicated a
crosstalk between AR and ERBB2 signaling for elevating
cell proliferation in TNBC [305]. AR has been
controversially suggested to be capable of showing
anti-proliferative activity in ER-positive tumors, and its
status was found to be inked to favorable outcome in
ER-positive breast cancer [306–308]. Overall, AR has
been defined to be linked to a transcription factor that is
Table 4 Clinical trials for treating the HER2 mutation positive patients by irreversible pan-ErbB tyrosine kinase inhibitor (Neratinib;
HKI-272). Tables and data are adopted from clinicaltrials.gov. (https://clinicaltrials.gov/)
Status of trail Condition Interventions of clinical trial Phase Completion time
Completed • BC
• Advanced solid tumors
• Drug: Neratinib and vinorelbine Phases 1 and 2 2018
Completed • Breast neoplasms • Drug: Neratinib Phase 2 2018
Completed • Advanced BC • Drug: HKI-272 and trastuzumab Phases 1 and 2 2018
Completed • Advanced BC
• Advanced solid tumors, breast neoplasms
• Drug: HKI-272 and paclitaxel Phases 1 and 2 2018
Active, not recruiting • BC • Drug: Neratinib and placebo Phase 3 2020
Completed • BC • Drug: Neratinib and capecitabine Phases 1 and 2 –
Recruiting • BC • Drug: HKI-272, Capecitabine, Ado
Trastuzumab Emtansine
Phase 2 2023
Completed • Breast neoplasms • Drug: Neratinib Phase 1 2007
Completed • BC • Drug: Neratinib, trastuzumab and
paclitaxel
Phase 2 2018
Completed • Advanced BC
• BC
• Drug: Neratinib, lapatinib and
capecitabine
Phase 2 2018
Completed • BC • Drug: Temsirolimus and neratinib Phases 1 and 2 2016
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capable of regulating genes implicated in opposite,
cellular processes; it was found to be able to induce or
inhibit cell proliferation and apoptosis, based upon the
concurrent signaling pathways activated [309–312].
AR-blockade in AR-positive TNBC has been revealed as
previously reported by phase II clinical trials, e.g., clin-
ical trial investigating abiraterone acetate plus prednis-
one (UCBG 12-1), [305], trial evaluating enzalutamide
(MDV30100-11) (Traina et al. 2018), and trial of bicalu-
tamide [313].
The anti-androgen agents (e.g., bicalutamide, enzaluta-
mide) provided novel approach for development of
therapeutic strategies in advanced breast cancer express-
ing AR. However, further development will have needed
in-depth understanding of mechanisms underlying AR
effect in the pathogenesis of BC. Increasing body of evi-
dence indicates that AR is able to interact with a set of
signaling pathways including MAPK pathways, cell cycle
and PI3K/AKT/mTOR, or Ras-dependent pathways and
many crucial molecules, such as pioneering factors
(FOXA1), PTEN, BRCA1, and BRCA2 are implicated in
carcinogens and progression of TNBC via interaction
with AR [314]. Targetable agates such as Src, PI3-K,
and/or MEK inhibitors or their rational combinations
with therapies based on hormone and chemotherapeutic
agents are currently provided for further assessment in
breast cancer [315].
Low-penetrant breast cancer
Many low-susceptibility loci have been identified through
genome association studies (GWAS). Easton et al. (2007)
detected susceptibility loci in some BC (i.e., FGFR2 at
10q26, a locus on 8q, LSP1 at 11p15, TNRC9/TOX3 at
16q12, MAP3K1 at 5q11), [302]. Hunter et al. (2007) rec-
ognized correlation of fibroblast growth factor receptor 2
(FGFR2) with sporadic postmenopausal BC and also ob-
served other susceptibility loci including TLR1/TLR6 (on
4p) and RELN (on 7q), [316]. A number of loci have been
previously discovered on chromosomes via GWAS includ-
ing 1p11.2 (rs11249433), 2q35 (rs13387042), 16q12
(rs3803662), 3p24 (rs4973768), 6q22.33 (rs2180341),
6q25.1 (rs2046210), 8q24 (rs13281615), and 17q23
(rs6504950), 14q24 (rs999737), as well as 5p15.33 (TERT
rs2736098), etc. Increasing evidence suggests that these
emerged single-nucleotide polymorphisms (SNPs) may be
associated with BC susceptibility [316].
Concluding remarks, the potential treatment
model of breast cancer and current and future
perspectives
GWAS and other studies revealed modifier alleles with
high (e.g., BRCA1, BRCA2, TP53, PTEN, etc.) to moder-
ate penetrance (e.g., BRIP1, CHEK2, ATM, and PALB2,
etc.) among population [317–324]. These modifier alleles
can be related to the malignant transformation of breast
epithelial cells, where they are capable of disrupting the
molecular and cellular pathways involved in regulation
of many biological process [324, 325]. The current re-
view indicated a growing body of evidence that suggests
multiple genetic modifiers of the human breast cancer,
of course other modifier alleles can exist. Nevertheless,
the majority of these modifiers needed more clarification
and in-depth understanding in terms of their mechanis-
tic roles in biology of breast cancer.
Molecular targeted therapy and immunotherapies are
attracting attention of researchers as they offer approach
for providing novel targets for future therapeutic
strategies.
Today, effective targeted therapies have been identified
for breast cancer that is believed to effectively block
various molecular pathways. Trastuzumab or Herceptin
has been proposed to contribute to the favorable efficacy
for neoadjuvant and adjuvant therapies in HER2-positive
breast cancer [326–329].
HER2 protein targeting has been found to be the most
efficient targeted therapy as its high expression is detect-
able in the surface of breast cancer cells, and its upregu-
lation is linked to malignant transformation and worst
overall survival of patients with breast cancer [330, 331].
Recombinant antibody of trastuzumab has been con-
firmed by FAD for targeting HER2-positive breast can-
cer, which is capable of binding juxtamembrane area of
HER-2 tyrosine kinase receptor, leading to the uncoup-
ling of the HER2/HER3 heterodimers and is conse-
quently involved in blocking downstream signaling and
cytotoxicity [331–333]. Trastuzumab-DM1 (TDM1) has
been proved to be persistently capable of inhibiting tras-
tuzumab sensitivity and resistance of HER2-positive cells
lines in breast cancer [331, 334]; it has been indicated to
be involved in breakdown of the blood-brain barrier.
Moreover, 264RAD antibody has been provided to be
used for integrin αvβ6 targeting, resulting in decreasing
progression of trastuzumab resistant in HER2-positive
breast cancer cells [330]. Bevacizumab or avastin has
been proved to be capable of inhibiting the development
of new blood vessels which are implicated in providing
energy supplies such as oxygen and nutrients to cancer
cells [331]. Targeted therapies for VEGF has been ap-
plied, where bevacizumab has been proved to be a thera-
peutic approach for metastatic breast cancer, which
prolongs progression-free survival, in comparison with
paclitaxel or docetaxel [335, 336].
Dual-targeted therapy using trastuzumab and pertuzu-
mab can be another strategy in this regard.
The dual targeting of HER receptors (HER1, HER2,
HER3) by applying antibody therapy may pave the way
for opening a novel therapeutic approach order to over-
come cetuximab resistance induced by cancer cells,
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therefore U3-1287 as an anti HER3 monoclonal antibody
was capable of reducing proliferation via inhibiting of
both MAPK and AKT pathways and diminishing signal-
ing from three HER receptors [337].
T-DM1 plays an important role in heavily pre-
treated patients with HER2-positive advanced breast
cancer and contributes to the breakdown of the
blood-brain barrier [326].
mTOR inhibitors (e.g., everolimus, ipatasertib, and
buparlisib) and CDK4/6 (e.g., palbociclib, ribociclib, and
abemaciclib) have been introduced to be capable of re-
versing the resistance to targeted agents and endocrine
agents. CDK4/6 is considered as a key role in regulating
cell cycle progression and is associated with tumorigen-
esis in breast cancer [326].
Regarding PARP inhibitors, talazoparib is recently
evaluated in phase III trial, where its binding to DNA
via trapping PARP–DNA complexes has been demon-
strated, indicating its potency in primary clinical practice
(NCT01945775), [338, 339]. Sunitinib has been indicated
to be potentially involved in suppression of angiogenesis,
proliferation of tumor cells, and migration, as well as de-
velopment and progression of basal like breast cancer cells
[331, 340]. Everolimus, as a m-TOR inhibitor, has been
proposed to inhibit cancer cells from getting energy [341].
PARP inhibitors have been also reported to attribute to a
great potential therapeutic strategy for theBRCA1/2-mu-
tated subgroup among patient suffering from TNBC
[326]. Overall, novel targeted agents have been provided
an opportunity for the development of targeted therapy in
terms of specific molecular subtypes of breast cancer, e.g.,
PI3K/AKT/mTOR, PARP, CDK4/6, VEGF, multiple ki-
nases, immune checkpoint (e.g., Keytruda [pembrolizu-
mab], anti PD-L1 antibody atezolizumab, etc.) and HER2
inhibitors [326, 338].
However, the intra- and/or intertumor heterogeneity
of the breast cancer showed its diversifying roles in the
tumor initiation and progression, where it has facilitated
the presence of diverse biomarkers in primary and meta-
static stage of tumors as well as in single tumor, leading
to difficulty in determining a favorable genetic signature
for all subtypes or each subtype, particularly tumor stem
cells [326]. Combination has been proposed to attribute
to an increased tumor cell killing, while also rises differ-
ent adverse events.
A large number of combination therapies are proposed
based on the agents which are capable of targeting the
PI3K/AKT/mTOR pathways, e.g., everolimus combined
to HER-2 or estrogen receptor, everolimus in combin-
ation with exemestane, combination of everolimus and
endocrine therapy, PI3K inhibitors combined to CDK4/6
inhibitors and endocrine therapy, etc. [243, 326, 342]
For instance, combination therapy regimens with
everolimus and HER-2 or estrogen receptor inhibitors
have been proposed for inhibiting mTOR pathway as fu-
ture targeted therapy to reverse sensitivity of breast can-
cer cells to previous therapeutic approaches, thus
leading to prevention of resistance mechanisms when
the mTOR pathway shows hyperactivity [331, 343]. It
has been demonstrated that a set of mutant genes such
as EGFR, BRAF, AKT, and PI3K in EGFR and PI3K/Akt/
MTOR pathways as well as pathway involving BRAF and
KRAS genes are attributed to activation of downstream
signaling pathways, leading to induction of high prolifer-
ation rate in cancer cells. ZSTK474 and sirolimus has
been combined as inhibitor of PI3K/Akt/MTOR path-
ways erlotinib and gefitinib as EGFR inhibitors for favor-
able inhibition of PI3K and EGFR pathway on MCF10a
isogenic cell linens exhibiting mutations in EGFR, PI3K,
BRAF, and AKT [344].
Trastuzumab/lapatinib/hormonal therapy has been
also confirmed as a combination therapeutic strategy for
hormonal receptor positive and increased HER2 protein
in luminal B/ HER2-enriched subtype of breast cancer
[331, 345].
As mentioned, tumor cells show such as breast cancer
show resistance to targeted agents in targeted therapy
and though molecular alterations like mutations and epi-
genetic alterations in molecular pathways have been re-
vealed, thus further development will need combination
of different pathway blockades for providing favorable
therapeutic outcomes [345–350].
Despite the advantages, like combination targeted
therapy, there are several challenges in terms of breast
cancer for providing a formula for future therapeutic
strategy that be simultaneously applied against various
subtypes of breast cancer in order to inhibit multiple
pathways involved. Further development will require
in-depth investigation of phenotypes of breast cancer
subtype, different mechanisms for cell survival, and fac-
tors involved in resistance to therapy that underlie main-
tenance of cancer cells and its influence in each breast
cancer subtype in order to provide promising and high
inclusive combination therapies [331].
Researchers reported mutations in specific genes
which may predispose individuals to developing certain
cancers. BRCA1 and BRCA2 are among the most fre-
quently mutated genes implicated in hereditary BC.
TP53 is another cancer predisposing gene, in which sig-
nificant mutation could be attributed to attribute to a
TNBC. Among other high-penetrant genes, a number of
rare germline mutations has been emerged that the most
notable of which are PTEN (Cowden syndrome);
STK11/LKB1 (Peutz-Jeghers). Cancer predisposing genes
and their pathways are importance for establishment of
preventative and therapeutic targets. Regarding the
widespread multigene panels, whole exome sequencing
is capable of providing evaluation of genetic function
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mutations for development of novel strategy in clinical
trials. Regarding molecular findings, ample deviance in-
dicated that a number of subgroups are sensitive to spe-
cific targeted agents (e.g., PI3K or PARP inhibitors). The
mechanistic roles of majority of mutations have been
poorly described in breast cancer. Further experimental
studies will require in depth-understanding of molecular
mechanism to empirically clarify their roles and cell
type-specific functions in breast cancer biology.
Targeting the mutant proteins involved in breast can-
cer can be an effective therapeutic approach for develop-
ing novel drugs. Further development will need genomic
profiling studies that are required to stratified tumors
based on similar tumor mutational burden (TMB) or
mutational signatures as compared to single driver
mutation [351].
This opens up opportunities for developing
immunotherapy-based strategies or alternative therap-
ies for cancers exhibiting mutations that are not ac-
tionable (i.e., RAs) or targetable. A number of studies
are required to focus on addressing the unaddressed
role of driver mutations in increasing genomic in-
stability (GI) and an inverse role [351]. Further devel-
opment will need in-depth understanding of the
molecular mechanisms, extent and pattern, and its in-
fluence in in breast cancer at the single-cell level to
provide effective therapeutic strategy.
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